Continue Reading With Our 7-Day Free Trial
Eli Lilly (NYSE:LLY) isn’t slowing down. After a quarter filled with blockbuster drug launches, accelerated global uptake of Mounjaro and Zepbound, and $12 billion in quarterly product revenue, the pharma heavyweight has turned its attention to gene therapy. The Eli Lilly Adverum acquisition is now official, as announced on December 9, 2025. With the deal closed, Lilly gets its hands on Ixo-vec—a gene therapy candidate targeting wet age-related macular degeneration (AMD)—plus pipeline assets aimed at rare diseases like retinitis pigmentosa and Friedreich’s ataxia. Lilly paid $3.56 in cash per Adverum share, with additional milestone-based payouts potentially bringing the total deal value to $12.47 per share.
For a company already running hot with obesity and diabetes treatments, this move may seem like a detour. But it’s not. This is a strategic expansion—one that folds into Lilly’s broader ambition to own more of the innovation stack. Let’s break down the key ways the Eli Lilly Adverum acquisition could deliver value beyond just pipeline filler.
Portfolio Diversification & Non-Incretin Revenue Streams
Eli Lilly’s growth has been explosive—no debate there. But the success of Mounjaro and Zepbound also creates a concentration risk. These two incretin-based therapies are projected to account for nearly two-thirds of Lilly’s sales by 2032. That’s a lot of eggs in one very lucrative basket. The Eli Lilly Adverum acquisition provides a counterweight, allowing Lilly to diversify into ophthalmology and rare disease markets where pricing pressure and competition look different than in the weight-loss category.
Gene therapy is still early in its commercial arc, but Ixo-vec represents an asset with clear clinical and economic rationale. Wet AMD is a leading cause of vision loss in people over 60. If Lilly can eventually move Ixo-vec through late-stage trials and onto the market, it would represent a high-margin, non-incretin revenue stream with limited overlap against existing products. That’s important, especially as Lilly prepares for possible GLP-1 price erosion from 2028 onward and expanding regulatory scrutiny in the U.S. The Eli Lilly Adverum acquisition could help hedge against future revenue volatility.
Vertical Integration Into Next-Gen Platforms
While Lilly has a well-oiled biologics and small-molecule engine, gene therapy is a newer frontier. Adverum’s assets give Lilly a foot in the door to AAV-mediated therapies—a space that has grown more attractive as delivery technologies have improved. Beyond Ixo-vec, Adverum’s early-stage programs for retinal and neurodegenerative diseases fit with Lilly’s R&D appetite. The move could allow Lilly to integrate gene therapy into its existing manufacturing and R&D systems without starting from scratch.
Lilly’s Q3 earnings already spotlighted new U.S. facilities coming online to support monoclonal antibodies and bioconjugates. That infrastructure can potentially be adapted for viral vector-based treatments over time, giving the company a vertically integrated base to support gene therapies from preclinical through commercial launch. If successful, this could compress development timelines and control costs—two major hurdles for gene therapy players. In that sense, the Eli Lilly Adverum acquisition is less about today’s earnings and more about tomorrow’s manufacturing muscle.
Expanding Retinal Disease Focus To Complement Neuroscience
Lilly is already leaning into the brain. Its Alzheimer’s drug Kisunla has just launched, with expectations that real-world use will scale up over the next 12–18 months. On the neuroscience side, the company is also trialing incretin-based molecules like brenipatide for alcohol use disorder, asthma, and potentially even obesity-linked CNS issues. So what does ophthalmology have to do with any of this?
A lot, actually. The eye is often referred to as an extension of the brain in clinical research. Conditions like AMD, retinitis pigmentosa, and even Friedreich’s ataxia involve degenerative pathways that overlap with neurological processes. Adding retinal gene therapy capabilities through the Eli Lilly Adverum acquisition could feed Lilly’s long-term neuroscience strategy—especially as the company explores treatments for neurodegeneration and rare genetic disorders.
Moreover, expanding into ophthalmology creates optionality. There are fewer entrenched competitors in gene therapy for the eye than in the broader CNS field. While companies like Roche (via Genentech) and Regeneron have made wet AMD a blockbuster space, none are combining gene therapy and neurology the way Lilly potentially could. That’s a strategic edge—and one that could mature nicely over the next decade.
Financial Leverage Without Balance Sheet Stress
Lilly didn’t need to do this deal. But it could—comfortably. The company has one of the cleanest balance sheets in large-cap pharma, with a debt/EBITDA ratio projected to fall below 1x in 2025. That gives it flexibility to pursue tuck-in deals without compromising capital allocation discipline. The Adverum acquisition fits that bill: the upfront cost was minimal at $3.56 per share (well below Adverum’s pre-announcement trading levels), and the bulk of the $12.47 per-share valuation is back-end loaded via milestones.
This approach aligns with Lilly’s stated strategy of avoiding megadeals while staying opportunistic. Recent buys like Dice Therapeutics and Versanis have followed a similar logic—small, focused bets that deepen platform capabilities rather than distract with integration risk. Financially, Lilly’s free cash flow yield sits at 1.8%, and its next-twelve-month EV/EBITDA multiple of ~24x remains elevated but justified by strong topline growth and margin expansion. The Eli Lilly Adverum acquisition likely won’t dent those metrics much, especially if the pipeline assets see development progress.
Final Thoughts: Strategic Optionality, But Execution Risk Looms
The Eli Lilly Adverum acquisition opens new doors—but also introduces new challenges. On one hand, it brings pipeline assets in gene therapy, diversifies revenue, and reinforces Lilly’s neuroscience ambitions. On the other hand, none of Adverum’s programs are near-term revenue drivers, and the gene therapy space is still grappling with high costs, slow regulatory paths, and mixed payer receptivity.
From a valuation standpoint, Lilly continues to trade at premium multiples. As of December 2025, its LTM EV/EBITDA stands at 31.7x and LTM P/E at a lofty 48x. That premium reflects investor belief in the GLP-1 franchise and the broader innovation platform—but it also raises the bar for new acquisitions to “move the needle.” Whether the Adverum assets can justify that bet will take years to play out.
For now, this deal looks like a long-term investment in strategic optionality—not a swing for immediate upside. Whether that proves visionary or just expensive depends on execution, and perhaps a little luck.
Disclaimer: We do not hold any positions in the above stock(s). Read our full disclaimer here.
